Page 1932 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

Index 1359

fracture assessment, 1172, 1173t Ulcer node syndromes, 719–720 infective endocarditis, 354–356
treatment of, 1173, 1173t plague, 719 clinical presentation, 354, 355f
multisystem tularemia, 719–720 etiology, 354
deciding on surgical intervention, 1121 Ulceroglandular tularemia, 747 pathophysiology, 354
priorities in, 1116–1121 Ultrafiltration, 933 mitral regurgitation, 350–351, 350f
adequacy of perfusion, Ultrasound predictors, static clinical presentation, 350–351
1118–1119, 1119t echocardiographic and, 263–264 diagnostic evaluation, 351
airway, oxygenation, ventilation, and Uncontrolled bleeding, salvage therapy for etiology, 350
cervical spine control, 1117 endoscopically, 1009–1010 management of, 351
cervical spine protection, 1118 Uniform Determination of Death Act, 838 pathophysiology, 350
detailed systematic assessment and United Network for Organ Sharing mitral stenosis, 348–350
https://kat.cr/user/tahir99/
definitive care, 1120 (UNOS), 1097 clinical presentation, 349
fracture stabilization, 1120 U.S. Strategic National Stockpile diagnostic evaluation, 349
locating source of internal (SNS), 57 management of, 349
hemorrhage, 1119 Unstable angina, 294 pathophysiology, 348–349, 349f
neurologic status, 1119–1120 Upper airway obstruction, 404–411 prosthetic valve dysfunction, 352–354
reevaluation and monitoring patient, anatomy of upper airway, 404, 405f structural failure of prosthetic
1120–1121 causes of valves, 354
surgical airway, 1117–1118, 1117f laryngeal, 407–409 thrombosis, 353–354, 353f
ventilation, 1118 nasal and pharyngeal, 406–410, 408t tricuspid regurgitation, 351–352
nutrition and, 1062 oropharyngeal, 406–407 clinical presentation, 352
in pregnancy, 1259 clinical presentation and initial evaluation, diagnostic evaluation, 352
Traumatic abdominal compartment 405–406 etiology, 351, 352f
syndrome, 1167–1168 complications of, 411 management of, 352
Traumatic air embolism, 1157 pathophysiology of upper airway pathophysiology, 352
Traumatic brain injury (TBI), 1122 obstruction, 405 Vancomycin, 548, 550
operative management of, and decompressive fixed upper airway obstruction, 405 Vancomycin intermediate Staphylococcus
craniectomy, 1134–1135 variable extrathoracic obstruction, 405 aureus (VISA), 547
primary and secondary, 1124, 1124f variable intrathoracic obstruction, 405 Variability, sources of, in quality
Triage Index, 91–92 treatment of, 410–411 measurement, 11
TRICC trial, 843 Upper gastrointestinal bleeding, 218, 219f, 1010 Variceal bleeding, 221, 223
Tricuspid regurgitation, 198, 199f, 351–352 Upper respiratory tract, life-threatening Variceal hemorrhage, 1010–1014
clinical presentation, 352 infections of, 676–688 acute, 1030–1031
diagnostic evaluation, 352 Urinalysis in patients with acute kidney endoscopic therapy, 1012–1013
etiology, 351, 352f injury, 924–925 management, 1010–1012, 1011ft
management of, 352 Urinary catheters, 25, 25t pharmacotherapy, 1012
pathophysiology, 352 Urinary tract infections (UTIs), 559, 645, salvage therapy for endoscopically
TRISS trauma score, 89 649, 696–703 uncontrolled bleeding,
Tuberculosis (TB), infection control and, 30 catheter-associated bacteriuria and 1009–1010
Tularemia, 719–720, 747, 748 candiduria, 702–703 Varicella zoster virus (VZV), 670,
typhoidal, 747 due to bacteria, 696–701, 697t, 698t 1300–1302, 1301f
ulceroglandular, 747 antimicrobial therapy, 698–700 infection control and, 30
Tumor lysis syndrome, 871, 871t, 877–878, complications, 700–701 Vascular access, obesity and, 1310
878f, 926, 965 emerging antimicrobial resistance in Vascular causes of acute renal
Tumor necrosis factor inhibition, use of, in enterobacteriaceae, 697–698, 697t failure, 922
critically ill patient, 1252 enterococci as urinary pathogens, 698 Vascular dysfunction, in sepsis, 565
Tumor necrosis factor-α (TNF-α), 604 microbiology, 696 Vascular injury, extremity trauma and,
Tunnel infection, 591 due to Candida, 701–702 1173, 1174f
2009 influenza A (H1N1) severe ARDS, Urolithiasis, 211 Vascular occlusion test (VOT), 245
ECMO and, 479–481 Vascular physiology, thrombosis factors
Type I error, 47 V and, 846
Type I (immediate) hypersensitivity Vaccine, oral polio, 672 Vascular surgery emergencies,
reactions, 1282–1283 Valvular dysfunction, 258, 275 1075–1076, 1075t
Type II error, 47 Valvular heart disease, 343–356 Vasculitis, 1247
Type IV, delayed-type hypersensitivity aortic regurgitation, 347–348 Vasoactive drug therapy, 315
reactions, 1283–1284 clinical presentation, 347 Vasogenic edema, 794
Typhlitis, 616–617 diagnostic evaluation, 347–348 corticosteroids for, 812–813
Typhoidal tularemia, 747 etiology, 347, 347f Vaso-occlusive crisis (VOC), 904
management of, 348 Vaso-occlusive pain crisis, sickle cell
U pathophysiology, 347 disease and, 906
Ubiquitous injury, 107–108, 108f aortic stenosis, 344–347 Vasopressin, 316
Ulcer(s) clinical presentation, 345 as option in endovascular treatment,
Meleney, 691 diagnostic evaluation, 345, 345t 220–221
peptis, 1014–1017, 1015f, 1016f etiology, 344, 344f Vasopressin antagonists, role of, 950
pressure, 1304 natural history, 344 Vasopressin-induced skin necrosis,
stress, 575 pathophysiology, 344 1286, 1286f

Index.indd 1359 23-01-2015 15:33:54